Phase IA Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) in Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Jul 2017
At a glance
- Drugs JS 001 (Primary)
- Indications Cholangiocarcinoma; Nasopharyngeal cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Junshi Biosciences
- 05 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
- 05 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.
- 13 Dec 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2016.